|
Jan 28 |
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS...
NCI-Led Study Shows Median PFS of 9.6 Months Results... |
|
Jan 22 |
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101...
Patent Enhances IP Estate for Lead Asset;... |
|
Jan 09 |
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint...
PDS Biotech Submits Amended Protocol for Phase 3... |
|
Dec 09 |
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan...
New Patent Grants Broad Composition Claims for... |
|
Dec 02 |
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)...
Company to Discuss Proposed Amendment to Phase 3... |
|
Nov 13 |
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update...
Company Announced Completion of VERSATILE-002 Phase 2... |
|
Nov 11 |
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering...
$5.3 million Upfront with up to an Additional $5.8... |
|
Nov 10 |
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01AD...
Translational study shows that multiple... |
|
Nov 06 |
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results...
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Oct 30 |
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC...
Three abstracts accepted for presentation,... |
|
Oct 29 |
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer...
Company aims to shorten time frame to make... |
|
Sep 18 |
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (C...
First combination therapy to report 29.5 months of... |
|
Sep 02 |
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference...
PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Aug 25 |
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer...
Median Overall Survival (mOS) of 39.3 months in... |
|
Aug 13 |
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update...
Multiple Abstracts Presented at the 2025... |
|
Aug 06 |
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results...
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Jul 10 |
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Sta...
Metastatic Colorectal Cancer Cohort in NCI-Led... |
|
Jun 09 |
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC...
Event to Discuss the Changing Landscape of HNSCC... |
|
Jun 09 |
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC...
Event to Discuss the Changing Landscape of HNSCC... |
|
Jun 02 |
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to T...
Median overall survival data in first-line... |
|
May 22 |
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HP...
Phase 2: Versamune® HPV with pembrolizumab as... |
|
May 20 |
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase...
PRINCETON, N.J., May 20, 2025 (GLOBE NEWSWIRE)... |
|
May 14 |
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update...
VERSATILE-003 Phase 3 Site Initiations Underway... |
|
May 09 |
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
PRINCETON, N.J., May 09, 2025 (GLOBE NEWSWIRE)... |
|
May 08 |
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annua...
Infectimune® studies funded by and performed by... |
|
May 07 |
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results...
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE)... |
|
Apr 23 |
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (AS...
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Apr 16 |
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting...
Update on American Association for Cancer... |
|
Apr 08 |
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annu...
NCI presentation to highlight IL-12 fused... |
|
Mar 27 |
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update...
Initiated VERSATILE-003 Phase 3 Clinical Trial... |
|
Mar 25 |
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference...
Updated time slot of 11:00 AM CT on Friday,... |
|
Mar 18 |
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results...
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Mar 13 |
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metasta...
Phase 1/2 trial evaluating the proprietary... |
|
Mar 11 |
PDS Biotech Leadership to Participate in March Conferences...
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Mar 07 |
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Ca...
First-ever HPV16-positive head and neck cancer... |
|
Feb 27 |
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules...
$11 Million Upfront with up to an Additional $11... |
|
Feb 26 |
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metas...
Median Overall Survival (mOS) of 42.4 months in... |
|
Feb 24 |
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer...
Data confirms Versamune® HPV has potential as a... |
|
Feb 20 |
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025...
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS... |
|
Feb 05 |
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Re...
FDA-cleared amended trial design; First site... |